Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

1397-89-3 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Amphotericin B
Cas No: 1397-89-3
USD $ 1.0-1.0 / Gram 1 Gram 10000 Gram/Day LIDE PHARMACEUTICALS LIMITED Contact Supplier
API Amphotericin B oral or injection grade
Cas No: 1397-89-3
No Data 100 Gram 100 Kilogram/Month Josun International Limited Contact Supplier
Amphotericin B 1397-89-3 supplier
Cas No: 1397-89-3
No Data 1 Milligram 100 Metric Ton/Year Nanjing Sunsure Chemical Technology Co., Ltd Contact Supplier
Amphotericin B (oral)
Cas No: 1397-89-3
No Data No Data Metric Ton/Day SHINING HEALTH GROUP LIMITED Contact Supplier
Amphotericin B 1397-89-3 supplier
Cas No: 1397-89-3
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier
Glucose pentaacetate CAS.1397-89-3
Cas No: 1397-89-3
USD $ 25.0-50.0 / Kilogram 5000 Kilogram 5000 Kilogram/Month Kono Chem Co.,Ltd Contact Supplier
Amphotericin B -- CHemwill
Cas No: 1397-89-3
USD $ 1.0-1.0 / Metric Ton 1 Metric Ton 5 Metric Ton/Day Chemwill Asia Co., Ltd. Contact Supplier
Amphotericin B
Cas No: 1397-89-3
No Data No Data Metric Ton/Day ORCHID CHEMICAL SUPPLIES LTD Contact Supplier
Amadis Chemical offer CAS#1397-89-3;CAT#A807588
Cas No: 1397-89-3
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
Amphotericin B 1397-89-3 /manufacturer/low price/high quality/in stock
Cas No: 1397-89-3
USD $ 15.0-16.0 / Kilogram 1 Kilogram 1-10 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier

1397-89-3 Usage


ChEBI: A macrolide antibiotic used to treat potentially life-threatening fungal infections.

Amphotericin B liposome

The effective component in amphotericin B liposome is amphotericin B. Its cholesterol content can enhance the stability of the drug to retain the amphotericin B content in the hydrophobic layer as much as possible and reduces its binding to the cholesterol of human cell membrane while enhances its binding to the ergosterol of fungal cells membrane, and thus playing the maximal bactericidal ability of amphotericin B. Its mechanism of action is similar to amphotericin B which is through binding to the fungal cell membrane sterol (mainly ergosterol), further increasing the membrane permeability, and causing release of important material inside the cells (e.g., potassium, amino acids and nucleotides) which lead to the deaths of fungal cells.
Amphotericin B liposome mainly contains three dosage forms:
(1) amphotericin B lipid complexes (crosslink of amphotericin B with liposome)
(2) amphotericin B liposome (use liposome to wrap the amphotericin B inside).
(3) amphotericin B colloidal dispersion (warp the mixture between cholesterol sulfates with the same amount of amphotericin B).
Inside the body, the preparations of these lipids are mostly distributed in the reticular endothelial tissue (such as the liver, spleen and lung tissue), reducing the drug distribution in the kidney tissues, and thereby reducing the nephrotoxicity of amphotericin B. In addition, blood creatinine levels rise and hypokalemia also becomes rare; the incidence of toxic effect related to the intravenous drip is also significantly lower than that of amphotericin B. Therefore, amphotericin B liposome keeps the high antibacterial activity of amphotericin B while reducing their toxicity.
The product has good antifungal activity against cryptococcus neoformans, candida albicans, candida tropical, yeast, aspergillus, coccidioidomyces immitis, Histoplasma, blastomyces demantitidis and Brazil blastomyces. However, it has no activity against bacteria, Rickettsia and virus. Part of the aspergillus has drug resistance with Skin and hair ringworms are mostly resistant to it.

Polyene antifungal antibiotics

Amphotericin B is a kind of polyene antifungal antibiotics isolated from the culture medium of the Streptomyces (Streptomycesnodosus) which is same substance as the “Lushanmycin” isolated from the actinomyces in the soil of LuShan in JiangXi province of China in 1974. It has significant inhibitory effect on the Cryptococcus neoformans, dermatitis budding yeast, histoplasma capsulatum, sporothrix schenkii, white candida and several kinds of nocardia. The MIC is generally ranged from 0.2 to 0.5 μg/ml. The molecular composition of amphotericin B contains 7 pairs of macrocyclic lactone of conjugated double bond as the ligands and the deoxidized amino hexose of mycosamine as the sugar groups which are connected with the glycosidic bonds. Owing to the existence of both an amino group and carboxyl group in the structure, it is a kind of amphiprotic substance. Its appearance is yellow or orange yellow powder; it is odorless or almost odorless, tasteless and hygroscopic. It is vulnerable to damage and lose function in the sunshine. It is gradually decomposed at over 170 °C and is also not stable at 37 °C. It is soluble in dimethyl sulfoxide (DMSO), slightly soluble in dimethylformamide, extremely slightly soluble in methanol, but insoluble in water, ethanol, and chloroform or ether. It can form salt in either neutral or acidic medium with increased water solubility but a decreased antibacterial activity. Its de-oxidation cholic acid salt complex is light yellow powder and can form gel-like solution in water for injection usage.
This product can be stably subject to long-term storage in dry, dark, cold conditions. However, its aqueous solution shouldn’t be maintained at room temperature for more than 24 h, and can also only stored under 4 °C for only one week. Under pH6.0~7.5, it has the strongest antimicrobial effect which decreases at low pH. Its antibacterial mechanism is by combining with the ergosterol on the fungal cell membrane, causing the damage of the membrane and increasing its permeability which further causes the release of cellular substances, therefore resulting in cell death. It is ineffective in treating bacteria due to the lack of ergosterol composition on the bacteria cell membrane. This product is not easy to be absorbed through oral administration and its plasma concentration can be maintained for more than 24 hours after intravenous injection drop wise. It is not easy to penetrate through the blood-brain barrier.
Amphotericin B is effective in treating almost all the kinds of fungi with a low incidence of drug-resistant strains. Its price is also relative low which makes it still exhibit high practical value even after its clinical application for more than 40 years. However, the obvious renal toxicity as well as related infusion toxicity (such as fever, chills, nausea, etc.) has greatly restricted amphotericin B rom being widely applied. To reduce the adverse reactions, it has been recently developed in abroad of three types of amphotericin B liposome formulations: amphotericin B liposome, amphotericin B liposome complexes (ABLC) and amphotericin B colloidal dispersion agent (ABCD). Research data have shown that the three kinds of drug formulations have significantly reduced toxicity of amphotericin B while guaranteeing its antifungal activity. In especial, they significantly reduced the incidence of renal toxicity so that can improve the patient's tolerance while guarantee the curative effect of the drug.

Storage and transport properties

Warehouse: ventilation, dry and low temperature.

Chemical properties

It is pale yellow to orange needle crystal or powder. It is insoluble in water, ethanol, but soluble in acidic DMF, DMSO, and slightly soluble in DMF, acidic or alkaline water-containing lower alcohol. It is almost odorless, almost tasteless, and easy to be damaged by the light, heat and acid.


1. The product has strong inhibitory effect on various kinds of fungal infection, such as Cryptococcus neoformans, dermatitis budding yeast, histoplasma capsulatum, sporothrix schenkii, white candida, mucor sp and Coccidioides immitis. The goods are the primary choice of drugs for treating deep fungal disease.
2. It is a kind of polyene antifungal drugs. This drug binds to the sterol located on the fungal cell membranes sterol, disrupting the membrane permeability, causing the leakage of bacteria intracellular potassium ion, nucleotides, amino acids and therefore playing bactericidal effect by disrupting the normal metabolism.


Toxic substances.


Amphotericin B is the first-choice drug for treating deep fungus infection with a broad antifungal spectrum. It has inhibitory effect on cryptococcus, coccidioidomyces immitis, candida albicans, and blastomyces with exhibiting bactericidal effect at high concentration, and therefore is a kind of drugs being effective in treating deep fungus infection. Major clinical indications are as follows:
1. It can be used for the treatment of cryptococcosis, North American blastomycosis, disseminated candidiasis, coccidioidomycosis, and histoplasmosis.
2. It can be used for the treatment of mucormycosis caused by the rhizopus genera, absidia, endomycopsis and the basidiobulus sp.
3. It can be used for the treatment of sporotrichum disease caused by schenker sporotrichosis.
4. It can be used for the treatment of aspergillosis caused by the Aspergillus fumigatus.
5. External preparation is suitable for treating chromomycosis, fungal infections infection after burning, respiratory tract candida, Aspergillus or cryptococcus infection, and fungal corneal ulcer.

Flammability and hazard characteristics

Combustible; Heating yields toxic nitrogen oxides smoke.


Polypeptide antibiotic active against gram positive bacteria. Antifungal.

Drug interactions

1, Adrenal cortical hormone, such drugs can be used in combination for controlling the adverse reactions of amphotericin B, but it is generally not recommended to applied both drugs at the same time for that it can amplify the symptoms of amphotericin B induced hypokalemia. If it is necessary to apply them at the same time, it is recommended to apply adrenal cortical hormone at its minimum dose and with the shortest period of treatment. Moreover, monitoring the potassium concentration and heart function of the patients is also demanded.
2, Digitalis glycosides, hypokalemia caused by this product can strengthen potential digitalis toxicity. Simultaneous application should subject to the close monitor of the blood potassium concentration and heart function.
3, Fluorine cytosine has synergetic effect with amphotericin B, but this product can increase the intake of the former one and do harm to it excretion through renal, and thus further amplifying the toxic effects of fluoride cytosine.
4. This product has antagonist effect in vitro with pyrrole antifungal drugs such as ketoconazolen, fluconazole and itraconazole.
5, Nephrotoxicity drugs such as aminoglycoside, antitumor drugs, capreomycin, polymyxin class and vancomycin can have their nephrotoxicity enhanced when used in combination with this drug.
6, Bone marrow inhibitor and radiotherapy can aggravate the anemia o patients, and therefore should be applied with reduced amount when used in combination with amphotericin B.
7, the hypokalemia induced by this product can strengthen the effect of neuromuscular blockers. Therefore, the monitor of potassium concentration is demanded when these two kinds of drugs are used in combination.
8, application of urine alkaline medicine can enhance the excretion of this product and prevent or reduce of possibility of the occurrence o renal tubular acidosis.

Acute toxicity

Vein-LD50 in rats: 11.3 mg/kg; Abdominal cavity-LD50 in mice: 27.74 mg/kg.

Brand name

Amphotec (Three Rivers); Fungizone (BristolMyers Squibb).

Toxicity grading

Highly Poisonous.

Fire extinguishing agent

Dry powder, foam, sand, carbon dioxide.


Amphotericin B is heptaene polyene antifungal originally discovered as a metabolite of Streptomyces nodosus in 1956. Amphotericin B acts by binding sterols in the cell membrane leading to the formation of transmembrane channels and subsequent ion leakage. Amphotericin B is poorly water soluble so has been developed for therapeutic use as a complex with desoxylate or in liposomes to improve bioavailability. Amphotericin B is widely used as a research reagent in diverse applications with over 15,000 literature citations.


Its gastrointestinal absorption is poor and unstable. During the initiation of treatment, intravenous drop 1~5 mg of amphotericin B every day, then gradually increase to 0.65 mg/kg every day after which the blood peak concentration reaches 2~4 mg/L. Its blood clearance half-life is about 24 hours with the protein binding rate being 91%~95%. This drug concentration of this product in the pleural effusion, ascites and synovial cavity liquid is usually lower than half of the blood drug concentration at the same period, and the drug concentration in the bronchial secretions is also low. This product has the highest drug concentration in the renal tissues, followed by liver, spleen, adrenal gland, lung, thyroid, heart, skeletal muscle, and pancreas, etc. This product is slowly excreted in the body through the kidneys with about 2% to 5% daily dosage being excreted in the form of prototype. Its excreted amount through urine within 7 days can account the 70% of the administrated amount. After stopping taking this drug, the drug excretion through urine will continue last for at least seven weeks with increased drug excretion amount in alkaline urine. This product is not easy to be cleaned through dialysis.
The above information is edited by the chemicalbook of Dai Xiongfeng.

Production methods

Streptomyces strains for is used as the target strain. It is subject to submerged aerobic fermentation in the liquid medium containing both carbohydrates and organic nitrogen source. Upon reaching a certain titer units, extract the amphotericin from the fermented liquid. Amphotericin contains two ingredients, A and B with composition of A having a small toxicity and weak antifungal effect which is not suitable for clinical purposes; Composition B has a strong effect, called as amphotericin B.

Side effects

1. During the process of vein drip or after intravenous drip, adverse reactions include chills, fever, severe headache, loss of appetite, nausea, vomiting, and sometimes reduced in blood pressure, dizziness, etc.
2. It can occur for almost all the patients of different degree of renal function impairment during the course of treatment. It can appear in the urine of red blood cells, white blood cells, proteins, and tube type, and increased blood urea nitrogen and creatinine, decreased creatinine clearance rate. It can also cause renal tubular acidosis.
3. The hypokalemia which is due to large amounts of potassium ions discharging through urine.
4. System blood toxicity reaction with normal red blood anemia, sometimes also including leukopenia or thrombocytopenia.
5. Liver toxicity which is relatively rare but can cause liver cell necrosis and also sometimes cause acute liver function failure.
6. The cardiovascular system reaction such as cardiac arrest or ventricular fibrillation during rapid vein drip. In addition, the electrolyte disorder caused by amphotericin B may also lead to the occurrence of arrhythmia. This product can easily lead to thrombophlebitis upon vein drip.
7. Nervous system toxicity reaction: intrathecal injection of this product can cause severe headaches, fever, vomiting, neck stiffness, lower limb pain and urinary retention with paraplegia of lower limb in severe cases.
8. Allergic reactions such as anaphylactic shock, rash occasionally occur.

Chemical Properties

Crystalline Yellow Solid

1397-89-3 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
Sigma-Aldrich (Y0000005)  AmphotericinB  European Pharmacopoeia (EP) Reference Standard 1397-89-3 Y0000005 1,880.19CNY Detail
Sigma-Aldrich (PHR1662)  AmphotericinB  pharmaceutical secondary standard; traceable to USP, PhEur 1397-89-3 PHR1662-500MG 2,737.80CNY Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017


1.1 GHS Product identifier

Product name amphotericin B

1.2 Other means of identification

Product number -
Other names LNS-AmB

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1397-89-3 SDS

1397-89-3Related news

Release of different Amphotericin B (cas 1397-89-3) formulations from PMMA bone cements and their activity against Candida biofilm09/04/2019

Amphotericin B is used for local delivery from polymethylmethacrylate to treat fungal prosthetic joint infections. The optimal amphotericin B formulation and the influence of different poragens in the bone cements are unknown. To investigate the necessary amount of amphotericin B in the bone cem...detailed

In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B (cas 1397-89-3) formulations: Heated Amphotericin B (cas 1397-89-3) and Amphotericin B (cas 1397-89-3)-loaded microemulsion09/03/2019

Amphotericin B (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting, while the less toxic lipid-based formulations such as AmBisome® are very expensive. Two different strategies t...detailed

Case ReportFungemia due to Fusarium solani under low-dose liposomal Amphotericin B (cas 1397-89-3) in a patient after cord blood transplantation☆09/02/2019

The introduction of the prophylactic use of antifungal drugs caused the increased occurrence of invasive fungal infections due to previously rare molds, such as fusariosis, after allogeneic hematopoietic stem cell transplantation. We herein report the case of a patient with diffuse large B-cell ...detailed

Evaluation of size-based distribution of drug and excipient in Amphotericin B (cas 1397-89-3) liposomal formulation09/01/2019

Conventional quantitation of drug content in the liposome formulation involves the breakdown of bulk liposomes, which ignores details on the distribution of the active pharmaceutical ingredient (API) and excipients in liposomes of different sizes. The objective of this study is to develop an ana...detailed

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields